Blog

Co-administered antibody improves penetration of antibody–dye conjugate into human cancers with implications for antibody–drug conjugates Guolan Lu, Naoki Nishio, and their team address a persistent problem: inadequate penetration of antibody-based cancer treatments into solid tumors. Though antibodies promise a more targeted attack on cancer, delivering them effectively remains a puzzle.     Current Obstacles: Penetration…Read more

Introduction to the Research and Authors Antibody−drug conjugates (ADCs) are prominent cancer treatments. The research, “Strategies for UF/DF-Based Impurity Removal in the Post-conjugation Purification of Antibody−Drug Conjugate”, conducted by Lara Fernandez-Cerezo, Melissa Holstein, and their team, seeks to address purification challenges in ADCs.     Understanding ADCs and Their Importance ADCs combine a small-molecule drug…Read more

Initiating Change with Early Testing    The workshop kicked off with a strong emphasis on early testing in ADC development. They explained that early TOX/PK tests, taken during the conjugation phase, could provide a clearer roadmap for later, pricier GLP tox stages. These proactive measures aim to protect substantial investments, ensuring money is well spent.…Read more

The Rise of ADCs and Their Current Challenges The recent surge in antibody-drug conjugates (ADC) approvals by the FDA, now totalling eleven, showcases their potential in targeted therapeutics. The majority of these ADCs are produced through cysteine-selective bioconjugation. However, there’s a prevalent challenge with many of these ADCs – they use maleimide functionalized linkers known…Read more